Biology of Incretins: GLP-1 and GIP

Gastroenterology

Volumn 132, Issue 6, 2007, Pages 2131-2157

  Baggio, Laurie L ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUGON; CAPSAICIN; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROMYCIN; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GANGLION BLOCKING AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; HORMONE ANTAGONIST; HORMONE RECEPTOR AFFECTING AGENT; IBOTENIC ACID; INCRETIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIRENZEPINE; PROGLUCAGON; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; ENERGY; ENERGY ABSORPTION; ENZYME DEGRADATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE STRUCTURE; GLUCAGON RELEASE; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIVER FUNCTION; METABOLITE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OSSIFICATION; OSTEOBLAST; PANCREAS; PANCREAS ISLET BETA CELL; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SATIETY; SIGNAL TRANSDUCTION; STOMACH EMPTYING; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34248223285     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.054     Document Type: Article

References (247)

1. Bayliss W.M., and Starling E.H. On the causation of the so-called 'peripheral reflex secretion' of the pancreas. Proc R Soc Lond Biol 69 (1902) 352-353
2. Moore B., Edie E.S., and Abram J.H. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1 (1906) 28-38
3. La Barre J. Sur les possibilites d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 12 (1932) 620-634
4. McIntyre N., Holsworth D.C., and Turner D.S. New interpretation of oral glucose tolerance. Lancet 2 (1964) 20-21
5. Elrick H., Stimmler L., Hlad Jr. C.J., and Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Invest 24 (1964) 1076-1082
6. Brown J.C., Dryburgh J.R., Ross S.A., and Dupre J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31 (1975) 487-532
7. Lauritsen K.B., Moody A.J., Christensen K.C., and Lindkaer Jensen S. Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. Scand J Gastroenterol 15 (1980) 833-840
8. Mojsov S., Weir G.C., and Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79 (1987) 616-619
9. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
10. White J.W., and Saunders G.F. Structure of the human glucagon gene. Nucl Acids Res 14 (1986) 4719-4730
11. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., and Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261 (1986) 11880-11889
12. Drucker D.J., and Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 263 (1988) 13475-13478
13. Efrat S., Teitelman G., Anwar M., Ruggiero D., and Hanahan D. Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells. Neuron 1 (1988) 605-613
14. St-Onge L., Sosa-Pineda B., Chowdhury K., Mansouri A., and Gruss P. Pax6 is required for differentiation of glucagon-producing a-cells in mouse pancreas. Nature 387 (1997) 406-409
15. Sander M., Neubuser A., Kalamaras J., Ee H.C., Martin G.R., and German M.S. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev 11 (1997) 1662-1673
16. Heller R.S., Stoffers D.A., Liu A., Schedl A., Crenshaw III E.B., Madsen O.D., and Serup P. The role of Brn4/Pou3f4 and Pax6 in forming the pancreatic glucagon cell identity. Dev Biol 268 (2004) 123-134
17. McKinnon C.M., Ravier M.A., and Rutter G.A. FoxO1 is required for the regulation of preproglucagon gene expression by insulin in pancreatic alpha -(TC1-9) cells. J Biol Chem 281 (2006) 39358-39369
18. Drucker D.J., and Brubaker P.L. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci U S A 86 (1989) 3953-3957
19. Drucker D.J., Jin T., Asa S.L., Young T.A., and Brubaker P.L. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol 8 (1994) 1646-1655
20. Brubaker P.L., Schloos J., and Drucker D.J. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139 (1998) 4108-4114
21. Yi F., Brubaker P.L., and Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280 (2005) 1457-1464
22. Rountree D.B., Ulshen M.H., Selub S., Fuller C.R., Bloom S.R., Ghatei M.A., and Lund P.K. Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection. Gastroenterology 103 (1992) 462-468
23. Hoyt E.C., Lund P.K., Winesett D.E., Fuller C.R., Ghatei M.A., Bloom S.R., and Ulshen M.H. Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 45 (1996) 434-439
24. Reimer R.A., and McBurney M.I. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 137 (1996) 3948-3956
25. Tappenden K.A., Thomson A.B., Wild G.E., and McBurney M.I. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. JPEN J Parenter Enteral Nutr 20 (1996) 357-362
26. Trinh D.K., Zhang K., Hossain M., Brubaker P.L., and Drucker D.J. Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium. Diabetes 52 (2003) 425-433
27. Hill M.E., Asa S.L., and Drucker D.J. Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Mol Endocrinol 13 (1999) 1474-1486
28. Lee Y.C., Asa S.L., and Drucker D.J. Glucagon gene 5′-flanking sequences direct expression of SV40 large T antigen to the intestine producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267 (1992) 10705-10708
29. Jin T., and Drucker D.J. The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. Mol Endocrinol 9 (1995) 1306-1320
30. Nian M., Drucker D.J., and Irwin D. Divergent regulation of human and rat proglucagon gene promoters in vivo. Am J Physiol 277 (1999) G829-G837
31. Rouille Y., Martin S., and Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270 (1995) 26488-26496
32. Parker J.C., Andrews K.M., Allen M.R., Stock J.L., and McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290 (2002) 839-843
33. Gelling R.W., Du X.Q., Dichmann D.S., Romer J., Huang H., Cui L., Obici S., Tang B., Holst J.J., Fledelius C., Johansen P.B., Rossetti L., Jelicks L.A., Serup P., Nishimura E., and Charron M.J. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100 (2003) 1438-1443
34. Furuta M., Yano H., Zhou A., Rouille Y., Holst J.J., Carroll R., Ravazzola M., Orci L., Furuta H., and Steiner D.F. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 94 (1997) 6646-6651
35. Myojo S., Tsujikawa T., Sasaki M., Fujiyama Y., and Bamba T. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro. J Gastroenterol 32 (1997) 300-305
36. Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J.J. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 34 (1989) 1411-1419
37. Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M., Ghatei M.A., and Bloom S.R. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (2001) 4244-4250
38. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 (2004) 546-558
39. Sowden G.L., Drucker D.J., Weinshenker D., and Swoap S.J. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol 292 (2006) R962-R970
40. Drucker D.J., Erlich P., Asa S.L., and Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93 (1996) 7911-7916
41. Tang-Christensen M., Larsen P.J., Thulesen J., Romer J., and Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6 (2000) 802-807
42. Lovshin J., Estall J., Yusta B., Brown T.J., and Drucker D.J. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 276 (2001) 21489-21499
43. Lovshin J.A., Huang Q., Seaberg R., Brubaker P.L., and Drucker D.J. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 145 (2004) 3495-3506
44. Rothenberg M.E., Eilertson C.D., Klein K., Zhou Y., Lindberg I., McDonald J.K., Mackin R.B., and Noe B.D. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J Biol Chem 270 (1995) 10136-10146
45. Rouille Y., Kantengwa S., Irminger J.C., and Halban P.A. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272 (1997) 32810-32816
46. Ugleholdt R., Poulsen M.L., Holst P.J., Irminger J.C., Orskov C., Pedersen J., Rosenkilde M.M., Zhu X., Steiner D.F., and Holst J.J. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem 281 (2006) 11050-11057
47. Mortensen K., Christensen L.L., Holst J.J., and Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114 (2003) 189-196
48. Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszova M., Petraki K., and Egan J.M. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol 290 (2006) E550-E559
49. Brubaker P.L. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 1070 (2006) 10-26
50. Unger R.H., Ohneda A., Valverde I., Eisentraut A.M., and Exton J. Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. J Clin Invest 47 (1968) 48-65
51. Hermann C., Goke R., Richter G., Fehmann H.C., Arnold R., and Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56 (1995) 117-126
52. Rocca A.S., and Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon- like peptide-1 secretion. Endocrinology 140 (1999) 1687-1694
53. Balks H.J., Holst J.J., von zur Muhlen A., and Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82 (1997) 786-790
54. Anini Y., Hansotia T., and Brubaker P.L. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143 (2002) 2420-2426
55. Anini Y., and Brubaker P.L. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144 (2003) 3244-3250
56. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
57. Roberge J.N., and Brubaker P.L. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128 (1991) 3169-3174
58. Anini Y., and Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52 (2003) 252-259
59. Reimann F., and Gribble F.M. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51 (2002) 2757-2763
60. Gribble F.M., Williams L., Simpson A.K., and Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52 (2003) 1147-1154
61. Dhanvantari S., Seidah N.G., and Brubaker P.L. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10 (1996) 342-355
62. Orskov C., Wettergren A., and Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42 (1993) 658-661
63. Wettergren A., Pridal L., Wojdemann M., and Holst J.J. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept 77 (1998) 83-87
64. Orskov C., Rabenhoj L., Wettergren A., Kofod H., and Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43 (1994) 535-539
65. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., and Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
66. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
67. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
68. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 (1995) 952-957
69. Hansen L., Deacon C.F., Orskov C., and Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999) 5356-5363
70. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
71. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97 (2000) 6874-6879
72. Turner A.J., Isaac R.E., and Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23 (2001) 261-269
73. Plamboeck A., Holst J.J., Carr R.D., and Deacon C.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48 (2005) 1882-1890
74. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regul Pept 128 (2005) 117-124
75. Ruiz-Grande C., Alarcon C., Alcantara A., Castilla C., Lopez Novoa J.M., Villanueva-Penacarrillo M.L., and Valverde I. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25 (1993) 612-616
76. Orskov C., Andreasen J., and Holst J.J. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 74 (1992) 379-384
77. Meier J.J., Nauck M.A., Kranz D., Holst J.J., Deacon C.F., Gaeckler D., Schmidt W.E., and Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 (2004) 654-662
78. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., and Marks V. Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 138 (1993) 159-166
79. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
80. Xiao Q., Boushey R.P., Drucker D.J., and Brubaker P.L. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117 (1999) 99-105
81. Ranganath L.R., Beety J.M., Morgan L.M., Wright J.W., Howland R., and Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut 38 (1996) 916-919
82. Ranganath L., Norris F., Morgan L., Wright J., and Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci (Lond) 96 (1999) 335-342
83. Vaag A.A., Holst J.J., Volund A., and Beck-Nielsen H.B. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon- like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135 (1996) 425-432
84. Vilsboll T., Agerso H., Krarup T., and Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88 (2003) 220-224
85. Mayo K.E., Miller L.J., Bataille D., Dalle S., Goke B., Thorens B., Drucker D.J., and International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55 (2003) 167-194
86. Sandhu H., Wiesenthal S.R., MacDonald P.E., McCall R.H., Tchipashvili V., Rashid S., Satkunarajah M., Irwin D.M., Shi Z.Q., Brubaker P.L., Wheeler M.B., Vranic M., Efendic S., and Giacca A. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48 (1999) 1045-1053
87. Montrose-Rafizadeh C., Avdonin P., Garant M.J., Rodgers B.D., Kole S., Yang H., Levine M.A., Schwindinger W., and Bernier M. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140 (1999) 1132-1140
88. Hallbrink M., Holmqvist T., Olsson M., Ostenson C.G., Efendic S., and Langel U. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta 1546 (2001) 79-86
89. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89 (1992) 8641-8645
90. Drucker D.J., Philippe J., Mojsov S., Chick W.L., and Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84 (1987) 3434-3438
91. Wheeler M.B., Lu M., Dillon J.S., Leng X.-H., Chen C., and Boyd III A.E. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133 (1993) 57-62
92. Holz G.G., Leech C.A., and Habener J.F. Activation of a cAMP-regulated Ca2+-signaling pathway in pancreatic b-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270 (1995) 17749-17757
93. Baggio L.L., Kim J.G., and Drucker D.J. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53 Suppl 3 (2004) S205-S214
94. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., and Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268 (1993) 19650-19655
95. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., and Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 (1996) 1254-1258
96. Holst J.J., Orskov C., Nielsen O.V., and Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211 (1987) 169-174
97. Wang Y., Perfetti R., Greig N.H., Holloway H.W., DeOre K.A., Montrose-Rafizadeh C., Elahi D., and Egan J.M. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99 (1997) 2883-2889
98. Li Y., Cao X., Li L.X., Brubaker P.L., Edlund H., and Drucker D.J. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 (2005) 482-491
99. Alarcon C., Wicksteed B., and Rhodes C.J. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 49 (2006) 2920-2929
100. Fehmann H.-C., and Habener J.F. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130 (1992) 159-166
101. Wang X., Cahill C.M., Pineyro M.A., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140 (1999) 4904-4907
102. Wang H., Iezzi M., Theander S., Antinozzi P.A., Gauthier B.R., Halban P.A., and Wollheim C.B. Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells. Diabetologia 48 (2005) 720-731
103. Holz G.G., Kuhtreiber W.M., and Habener J.F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361 (1993) 362-365
104. Fehmann H.C., and Habener J.F. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett 279 (1991) 335-340
105. Heller R.S., Kieffer T.J., and Habener J.F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46 (1997) 785-791
106. Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., and Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19 (1996) 580-586
107. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., Hufner M., and Schmiegel W.H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 (2002) 1239-1246
108. Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 (2003) 1444-1455
109. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
110. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., and Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47 (2004) 806-815
111. Farilla L., Bulotta A., Hirshberg B., Li Calzi S., Khoury N., Noushmehr H., Bertolotto C., Di Mario U., Harlan D.M., and Perfetti R. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
112. Yusta B., Baggio L.L., Estall J.L., Koehler J.A., Holland D.P., Li H., Pipeleers D., Ling Z., and Drucker D.J. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4 (2006) 391-406
113. Holz G.G., and Chepurny O.G. Diabetes outfoxed by GLP-1?. Sci STKE 2005 (2005) pe2
114. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17 (2003) 161-171
115. Buteau J., Foisy S., Joly E., and Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003) 124-132
116. Park S., Dong X., Fisher T.L., Dunn S., Omer A.K., Weir G., and White M.F. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281 (2006) 1159-1168
117. Kodama S., Toyonaga T., Kondo T., Matsumoto K., Tsuruzoe K., Kawashima J., Goto H., Kume K., Kume S., Sakakida M., and Araki E. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice. Biochem Biophys Res Commun 327 (2005) 1170-1178
118. Buteau J., Spatz M.L., and Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 55 (2006) 1190-1196
119. Wang Q., and Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 (2002) 1263-1273
120. Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J., Walker J., Lin X., White M., and Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17 (2003) 1575-1580
121. Schirra J., Sturm K., Leicht P., Arnold R., Goke B., and Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7- 36)amide in humans. J Clin Invest 101 (1998) 1421-1430
122. Ling Z., Wu D., Zambre Y., Flamez D., Drucker D.J., Pipeleers D.G., and Schuit F.C. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438 (2001) 382-387
123. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
124. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., Moller M., and Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) R848-R856
125. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., Abusnana S., Rossi M., Small C.J., Goldstone A.P., Taylor G.M., Sunter D., Steere J., Choi S.J., Ghatei M.A., and Bloom S.R. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140 (1999) 244-250
126. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., and Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
127. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., Ghatei M.A., and Bloom S.R. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
128. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
129. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
130. Deacon C.F., Pridal L., Klarskov L., Olesen M., and Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271 (1996) E458-E464
131. Balkan B., and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol 279 (2000) R1449-R1454
132. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol 286 (2004) R269-R272
133. Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
134. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., Benhamed F., Gremeaux T., Drucker D.J., Kahn C.R., Girard J., Tanti J.F., Delzenne N.M., Postic C., and Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115 (2005) 3554-3563
135. Perry T., Haughey N.J., Mattson M.P., Egan J.M., and Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302 (2002) 881-888
136. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., and Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 (2003) 1173-1179
137. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
138. Meier J.J., Gallwitz B., Salmen S., Goetze O., Holst J.J., Schmidt W.E., and Nauck M.A. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 2719-2725
139. Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., and McDonald T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44 (1995) 626-630
140. Wishart J.M., Horowitz M., Morris H.A., Jones K.L., and Nauck M.A. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 19 (1998) 1049-1053
141. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., and Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997) E981-E988
142. Meier J.J., Kemmeries G., Holst J.J., and Nauck M.A. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54 (2005) 2212-2218
143. Barragan J.M., Eng J., Rodriguez R., and Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277 (1999) E784-E791
144. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., Hollenberg A.N., Baggio L., Saper C.B., Drucker D.J., and Elmquist J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
145. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., Drucker D.J., and Elmquist J.K. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23 (2003) 2939-2946
146. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
147. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., and Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 281 (2001) E155-E161
148. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
149. Meier J.J., and Nauck M.A. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21 (2005) 91-117
150. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., and Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 287 (2004) E1209-E1215
151. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., and Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
152. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
153. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T., and Shannon R.P. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317 (2006) 1106-1113
154. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker D.J., and Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144 (2003) 2242-2252
155. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., and Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
156. Ruiz-Grande C., Alarcn C., Mzrida E., and Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13 (1992) 13-16
157. Villanueva-Penacarrillo M.L., Marquez L., Gonzalez N., Diaz-Miguel M., and Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33 (2001) 73-77
158. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., and Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999) 1026-1034
159. Ding X., Saxena N.K., Lin S., Gupta N.A., and Anania F.A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2006) 173-181
160. Furnsinn C., Ebner K., and Waldhausl W. Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38 (1995) 864-867
161. Nakagawa Y., Kawai K., Suzuki H., Ohashi S., and Yamashita K. Glucagon-like peptide-1(7-36)amide and glycogen synthesis in the liver. Diabetologia 39 (1996) 1241-1242
162. D'alessio D.A., Kahn S.E., Leusner C.R., and Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93 (1994) 2263-2266
163. Meneilly G.S., McIntosh C.H., Pederson R.A., Habener J.F., Gingerich R., Egan J.M., Finegood D.T., and Elahi D. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24 (2001) 1951-1956
164. Egan J.M., Meneilly G.S., Habener J.F., and Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87 (2002) 3768-3773
165. Orskov L., Holst J.J., Moller J., Orskov C., Moller N., Alberti K.G., and Schmitz O. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 39 (1996) 1227-1232
166. Toft-Nielson M., Madsbad S., and Holst J.J. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45 (1996) 552-556
167. Larsson H., Holst J.J., and Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160 (1997) 413-422
168. Ryan A.S., Egan J.M., Habener J.F., and Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83 (1998) 2399-2404
169. Vella A., Shah P., Reed A.S., Adkins A.S., Basu R., and Rizza R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45 (2002) 1410-1415
170. Prigeon R.L., Quddusi S., Paty B., and D'Alessio D.A. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: an extrapancreatic effect of an incretin hormone. Am J Physiol 285 (2003) E701-E707
171. Larsen P.J., Tang-Christensen M., and Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138 (1997) 4445-4455
172. MacLusky N.J., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F., Asa S.L., and Drucker D.J. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 141 (2000) 752-762
173. Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., and Roman R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21 (2003) 1125-1135
174. Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., and Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89 (2004) 3055-3061
175. Rolin B., Deacon C.F., Carr R.D., and Ahren B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 494 (2004) 283-288
176. Deacon C.F., Plamboeck A., Moller S., and Holst J.J. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol 282 (2002) E873-E879
177. Meier J.J., Gethmann A., Nauck M.A., Gotze O., Schmitz F., Deacon C.F., Gallwitz B., Schmidt W.E., and Holst J.J. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol 290 (2006) E1118-E1123
178. Vahl T.P., Paty B.W., Fuller B.D., Prigeon R.L., and D'Alessio D.A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88 (2003) 1772-1779
179. Nikolaidis L.A., Elahi D., Shen Y.T., and Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol 289 (2005) H2401-H2408
180. Jepeal L.I., Fujitani Y., Boylan M.O., Wilson C.N., Wright C.V., and Wolfe M.M. Cell-specific expression of glucose-dependent-insulinotropic polypeptide is regulated by the transcription factor PDX-1. Endocrinology 146 (2005) 383-391
181. Buchan A.M., Polak J.M., Capella C., Solcia E., and Pearse A.G.E. Electron immunochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 56 (1978) 37-44
182. Besterman H.S., Cook G.C., Sarson D.L., Christofides N.D., Bryant M.G., Gregor M., and Bloom S.R. Gut hormones in tropical malabsorption. BMJ 2 (1979) 1252-1255
183. Fushiki T., Kojima A., Imoto T., Inoue K., and Sugimoto E. An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats. J Nutr 122 (1992) 2367-2373
184. Orskov C., Wettergren A., and Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31 (1996) 665-670
185. Ross S.A., Brown J.C., and Dupre J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26 (1977) 525-529
186. Deacon C.F., Nauck M.A., Meier J., Hucking K., and Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85 (2000) 3575-3581
187. Deacon C.F., Danielsen P., Klarskov L., Olesen M., and Holst J.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50 (2001) 1588-1597
188. Vilsboll T., Agerso H., Lauritsen T., Deacon C.F., Aaboe K., Madsbad S., Krarup T., and Holst J.J. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137 (2006) 168-172
189. Yamada Y., Hayami T., Nakamura K., Kaisaki P.J., Someya Y., Wang C.Z., Seino S., and Seino Y. Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 29 (1995) 773-776
190. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., and Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133 (1993) 2861-2870
191. Lynn F.C., Pamir N., Ng E.H., McIntosh C.H., Kieffer T.J., and Pederson R.A. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50 (2001) 1004-1011
192. Wheeler M.B., Gelling R.W., Hinke S.A., Tu B., Pederson R.A., Lynn F., Ehses J., and McIntosh C.H. Characterization of the carboxyl-terminal domain of the rat glucose- dependent insulinotropic polypeptide (GIP) receptor. A role for serines 426 and 427 in regulating the rate of internalization. J Biol Chem 274 (1999) 24593-24601
193. Ding W.G., and Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46 (1997) 615-621
194. Gromada J., Bokvist K., Ding W.G., Holst J.J., Nielsen J.H., and Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47 (1998) 57-65
195. Kashima Y., Miki T., Shibasaki T., Ozaki N., Miyazaki M., Yano H., and Seino S. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276 (2001) 46046-46053
196. Ehses J.A., Lee S.S., Pederson R.A., and McIntosh C.H. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 276 (2001) 23667-23673
197. Ehses J.A., Pelech S.L., Pederson R.A., and McIntosh C.H. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277 (2002) 37088-37097
198. Kim S.J., Choi W.S., Han J.S., Warnock G., Fedida D., and McIntosh C.H. A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J Biol Chem 280 (2005) 28692-28700
199. Wang Y., Montrose-Rafizadeh C., Adams L., Raygada M., Nadiv O., and Egan J.M. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 116 (1996) 81-87
200. Tseng C.C., Kieffer T.J., Jarboe L.A., Usdin T.B., and Wolfe M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98 (1996) 2440-2445
201. Gelling R.W., Coy D.H., Pederson R.A., Wheeler M.B., Hinke S., Kwan T., and McIntosh C.H. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Peptides 69 (1997) 151-154
202. Baggio L., Kieffer T.J., and Drucker D.J. GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice. Endocrinology 141 (2000) 3703-3709
203. Lewis J.T., Dayanandan B., Habener J.F., and Kieffer T.J. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 141 (2000) 3710-3716
204. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., Kuroe A., Tsuda K., Hashimoto H., Yamashita T., Jomori T., Tashiro F., Miyazaki J., and Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 96 (1999) 14843-14847
205. Kim S.J., Winter K., Nian C., Tsuneoka M., Koda Y., and McIntosh C.H. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J Biol Chem 280 (2005) 22297-22307
206. Trumper A., Trumper K., Trusheim H., Arnold R., Goke B., and Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15 (2001) 1559-1570
207. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174 (2002) 233-246
208. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Demuth H.U., Pederson R.A., Winter K.D., and McIntosh C.H. Glucose-dependent Insulinotropic Polypeptide (GIP) Promotes {beta}-(INS-1) cell survival via cyclic AMP-mediated caspase-3 inhibition and regulation of p38 MAP kinase. Endocrinology 144 (2003) 4433-4445
209. Nyberg J., Anderson M.F., Meister B., Alborn A.M., Strom A.K., Brederlau A., Illerskog A.C., Nilsson O., Kieffer T.J., Hietala M.A., Ricksten A., and Eriksson P.S. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25 (2005) 1816-1825
210. Yip R.G.C., Boylan M.O., Kieffer T.J., and Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 139 (1998) 4004-4007
211. Creutzfeldt W., Ebert R., Willms B., Frerichs H., and Brown J.C. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 14 (1978) 15-24
212. Salera M., Giacomoni P., Pironi L., Cornia G., Capelli M., Marini A., Benfenati F., Miglioli M., and Barbara L. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 55 (1982) 329-336
213. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., Fushiki T., Holst J.J., Makino M., Tashita A., Kobara Y., Tsubamoto Y., Jinnouchi T., Jomori T., and Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8 (2002) 738-742
214. Gault V.A., Irwin N., Green B.D., McCluskey J.T., Greer B., Bailey C.J., Harriott P., O'Harte F.P., and Flatt P.R. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 (2005) 2436-2446
215. Irwin N., Gault V.A., Green B.D., Greer B., McCluskey J.T., Harriott P., O'Harte F.P., and Flatt P.R. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol Chem 385 (2004) 845-852
216. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., Mulloy A.L., Rasmussen H., Qin F., Ding K.H., and Isales C.M. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141 (2000) 1228-1235
217. Bollag R.J., Zhong Q., Ding K.H., Phillips P., Zhong L., Qin F., Cranford J., Mulloy A.L., Cameron R., and Isales C.M. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 177 (2001) 35-41
218. Xie D., Cheng H., Hamrick M., Zhong Q., Ding K.H., Correa D., Williams S., Mulloy A., Bollag W., Bollag R.J., Runner R.R., McPherson J.C., Insogna K., and Isales C.M. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37 (2005) 759-769
219. Zhong Q., Itokawa T., Sridhar S., Ding K.H., Xie D., Kang B., Bollag W.B., Bollag R.J., Hamrick M., Insogna K., and Isales C.M. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol 292 (2007) E543-E548
220. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., Byrjalsen I., Krarup T., Holst J.J., and Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18 (2003) 2180-2189
221. Nauck M.A., Bartels E., Orskov C., Ebert R., and Creutzfeldt W. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects. Digestion 52 (1992) 214-221
222. Mazzocchi G., Rebuffat P., Meneghelli V., Malendowicz L.K., Tortorella C., Gottrdo G., and Nussdorfer G. Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway. Peptides 20 (1999) 589-594
223. Lacroix A., Bolte E., Tremblay J., Dupre J., Poitras P., Fournier H., Garon J., Garrel D., Bayard F., and Taillefer R. Gastric inhibitory polypeptide-dependent cortisol hypersecretion-a new cause of Cushing's syndrome. N Engl J Med 327 (1992) 974-980
224. Zhong Q., Bollag R.J., Dransfield D.T., Gasalla-Herraiz J., Ding K.H., Min L., and Isales C.M. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides 21 (2000) 1427-1432
225. Todd J.F., Edwards C.M., Ghatei M.A., Mather H.M., and Bloom S.R. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Colch) 95 (1998) 325-329
226. Meneilly G.S., McIntosh C.H., Pederson R.A., Habener J.F., Gingerich R., Egan J.M., and Elahi D. Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes. Diabetes Care 24 (2001) 964-965
227. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 267 (1992) 7402-7405
228. Fineman M.S., Bicsak T.A., Shen L.Z., Taylor K., Gaines E., Varns A., Kim D., and Baron A.D. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 (2003) 2370-2377
229. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
230. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
231. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
232. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., and Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (2005) 559-569
233. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., Brodows R., and Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 (2004) 259-267
234. Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., Rungby J., Landau B.R., and Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
235. Nauck M.A., Hompesch M., Filipczak R., Le T.D., Zdravkovic M., and Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 114 (2006) 417-423
236. Gedulin B.R., Smith P., Prickett K.S., Tryon M., Barnhill S., Reynolds J., Nielsen L.L., Parkes D.G., and Young A.A. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48 (2005) 1380-1385
237. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., and Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284 (2001) 501-506
238. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 100 (2003) 6825-6830
239. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., and Zhang B.B. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
240. Ahren B., and Hughes T.E. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 (2005) 2055-2059
241. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., and Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
242. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
243. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
244. Charbonnel B., Karasik A., Liu J., Wu M., and Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
245. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., and Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
246. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., and Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
247. Rosenstock J., Brazg R., Andryuk P.J., Lu K., and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568